CD52 expression	Prolymphocytic Leukemia	CD52 expression	Prolymphocytic Leukemia	alemtuzumab Sensitive: A2 - Guideline NCCN - 4 weeks (New A2) alemtuzumab Sensitive : A2 NCCN - 4wk	alemtuzumab Sensitive: A2 - Guideline NCCN - 4 weeks alemtuzumab Sensitive : A2 NCCN - 4 weeks - (New A2)
No biomarker	Prolymphocytic Leukemia	No biomarker	Prolymphocytic Leukemia	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2
No biomarker	Prolymphocytic Leukemia	No biomarker	Prolymphocytic Leukemia	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2
No biomarker	Prolymphocytic Leukemia	No biomarker	Prolymphocytic Leukemia	pentostatin Sensitive: A2 - Guideline pentostatin Sensitive : A2	pentostatin Sensitive: A2 - Guideline pentostatin Sensitive : A2
NOTCH1 mutation	Prolymphocytic Leukemia	NOTCH1 mutation	Prolymphocytic Leukemia	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3
JAK3 mutation	Prolymphocytic Leukemia	JAK3 mutation	Prolymphocytic Leukemia	venetoclax + ruxolitinib Sensitive: C3 – Early Trials venetoclax + ruxolitinib Sensitive : C3	venetoclax + ruxolitinib Sensitive: C3 – Early Trials venetoclax + ruxolitinib Sensitive : C3
CDKN2A deletion	Prolymphocytic Leukemia	CDKN2A deletion	Prolymphocytic Leukemia	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4
STAT5B N642H	Prolymphocytic Leukemia	STAT5B N642H	Prolymphocytic Leukemia	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4
TCL1A rearrangement	Prolymphocytic Leukemia	TCL1A rearrangement	Prolymphocytic Leukemia	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4
RAD50 Y625	Prolymphocytic Leukemia	RAD50 Y625	Prolymphocytic Leukemia	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4
ATM D2721N	Prolymphocytic Leukemia	ATM D2721N	Prolymphocytic Leukemia	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4
PAK4 deletion	Prolymphocytic Leukemia	PAK4 deletion	Prolymphocytic Leukemia	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4
BRAF V600E	Prolymphocytic Leukemia	BRAF V600E	Prolymphocytic Leukemia	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4	alemtuzumab Resistant: C4 – Case Studies alemtuzumab Resistant : C4
BRAF V600E	Prolymphocytic Leukemia	BRAF V600E	Prolymphocytic Leukemia	venetoclax Resistant: C4 – Case Studies venetoclax Resistant : C4	venetoclax Resistant: C4 – Case Studies venetoclax Resistant : C4
BRAF V600E	Prolymphocytic Leukemia	BRAF V600E	Prolymphocytic Leukemia	dasatinib Resistant: C4 – Case Studies dasatinib Resistant : C4	dasatinib Resistant: C4 – Case Studies dasatinib Resistant : C4
BRAF V600E	Prolymphocytic Leukemia	BRAF V600E	Prolymphocytic Leukemia	vemurafenib Sensitive: C4 – Case Studies vemurafenib Sensitive : C4	vemurafenib Sensitive: C4 – Case Studies vemurafenib Sensitive : C4

Prolymphocytic Leukemia

Associations(16)

Associations
(16)